Why Abzena?
Our focused approach.
We partner with you to apply the right set of bioassays and analytics to assess the ‘developability’ of your lead candidates. Our comprehensive approach to bioconjugate and ADC development ensures that the candidates you take forward have reduced liabilities and a de-risked development path.
We have worked with hundreds of bioconjugate candidates and have the experience to help inform your approach and reduce project timescales by having a developability approach covering specificity, functionality, safety, and manufacturability.
Our full-time equivalent (FTE) model provides you the flexibility to apply the necessary expertise to your project with data guiding the best approach to select the optl lead candidate for progression to cell line development and ADC manufacturing.
Our integrated end-to-end capabilities mean our design team can utilize information generated during our developability assessment to remove or reduce any liabilities in real-time and improve the developability profile of your drug, mitigating risks of major issues in the later development phases.
To select your best candidate for clinical development our team ensures that your ADC aligns with your required functional and safety profile by testing in standard, off-the-shelf, or custom-developed bioassays.
We also utilize an extensive range of assays to evaluate:
If your novel ADC and bioconjugate requires customized assays, our team has the know-how and expertise to develop them.
Full characterization of your ADC is assessed by standard and orthogonal assays to ensure that your molecule meets the critical parameters to support development, stability, and manufacture.
Additional assays to support the stability and safety assessment will guide the stage-specific selection of ADC candidates through to the final lead selection.
Abzena can support you along every step of ADC development, from discovery through to manufacturing, with a focus on precision and efficiency. We specialize in cutting-edge bioconjugation methods that support the development of stable and effective ADCs. Through our proprietary technologies like ThioBridge™, which offers improved ADC design and delivery, we streamline the conjugation process, ensuring efficacy, safety, and scalability of your therapeutic.
ADCs and other bioconjugates are rapidly emerging as one of the fastest-growing development areas in biologic anti-cancer treatment. The bioconjugate asset you’re developing right now can make a real difference for human health. Let us apply our expertise to accelerate and maximize its potential.